NCT06518213Completed
Efficacy and Safety of First-line ART With BIC/FTC/TAF Introduced at the First Clinical Visit
Efficacy and Safety of First-line Antiretroviral Therapy (ART) With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) Introduced at the First Clinical Visit: a Real-life Retrospective Single Arm Single Center Study
Source: ClinicalTrials.gov · Last updated 24 Jul 2024
Brief summary (registry, in English)
Bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) is a recommended first-line antiretroviral regimen. Croatia has a centralized care for people living with HIV (PLWH) and all persons are seen and treated in a single center, preferably in a same-day initiation model whenever suitable. This retrospective cohort study evaluated antiretroviral therapy (ART) naïve PLWH who initiated BIC/FTC/TAF, in a same-day model. The goal of the study is to assess safety and efficacy of this model by collecting information from the electronic database of the Croatian HIV Reference Centre.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 112 (actual)
- First submitted
- 12 Jul 2024
- Start date
- 1 May 2019
- Primary completion date
- 31 Dec 2022
- Lead sponsor
- University Hospital for Infectious Diseases, Croatia
- Diseases
- HIV
- NCT number
- NCT06518213
What you commit to
- Study type: Observational
- Participants enrolled: 112
- From 1 May 2019 to the primary completion date, 31 Dec 2022
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- unacceptable interaction with a drug that the subject is already taking
Age
- persons under 18 years of age
Other
- people who are pregnant, breastfeeding or planning to become pregnant
Who the study is looking for
- HIV seropositivity confirmed by a fourth generation test
- the subject had not previously taken ART
- ART was started within 24 hours of the first examination
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Hospital for Infectious Diseases ''Dr. Fran Mihaljevic'' Coordinator of this site? Confirm its status | Zagreb | Croatia | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.